ARDS
Aridis Pharmaceuticals Inc
Price:  
0.31 
USD
Volume:  
33,389,508
United States | Biotechnology

ARDS WACC - Weighted Average Cost of Capital

The WACC of Aridis Pharmaceuticals Inc (ARDS) is 4.5%.

The Cost of Equity of Aridis Pharmaceuticals Inc (ARDS) is 102.6%.
The Cost of Debt of Aridis Pharmaceuticals Inc (ARDS) is 5%.

RangeSelected
Cost of equity80.8% - 124.4%102.6%
Tax rate26.2% - 27.0%26.6%
Cost of debt5.0% - 5.0%5%
WACC4.3% - 4.7%4.5%
WACC

ARDS WACC calculation

CategoryLowHigh
Long-term bond rate3.9%4.4%
Equity market risk premium4.6%5.6%
Adjusted beta16.7221.35
Additional risk adjustments0.0%0.5%
Cost of equity80.8%124.4%
Tax rate26.2%27.0%
Debt/Equity ratio
116.45116.45
Cost of debt5.0%5.0%
After-tax WACC4.3%4.7%
Selected WACC4.5%

ARDS's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for ARDS:

cost_of_equity (102.60%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (16.72) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.